Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28722241 | 1.00 | POLB (0.33) | POLBRAB9ANPC1SMN1; SMN2SMYD3 | |
| SCHEMBL23051971 | 1.00 | POLB (0.33) | POLBRAB9ANPC1SMN1; SMN2SMYD3 | |
| SCHEMBL28722803 | 0.94 | TACR3 (0.34) | POLBRAB9ASMYD3MMEJAK2 | |
| SCHEMBL23052262 | 0.94 | TACR3 (0.34) | POLBRAB9ASMYD3MMEJAK2 | |
| SCHEMBL23052264 | 0.94 | TACR3 (0.34) | POLBRAB9ASMYD3MMEJAK2 | |
| SCHEMBL29452761 | 0.94 | TACR3 (0.34) | POLBRAB9ASMYD3MMEJAK2 | |
| SCHEMBL23052252 | 0.92 | SLC8A1 (0.36) | POLBRAB9ASMN1; SMN2SMYD3MME | |
| SCHEMBL23052269 | 0.92 | SLC8A1 (0.36) | POLBRAB9ASMN1; SMN2SMYD3MME | |
| SCHEMBL23052268 | 0.92 | SLC8A1 (0.36) | POLBRAB9ASMN1; SMN2SMYD3MME | |
| SCHEMBL23052251 | 0.92 | SLC8A1 (0.36) | POLBRAB9ASMN1; SMN2SMYD3MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-09-29 | — | — | US | claimed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | claimed |
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-09-29 | — | — | US | disclosed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| CN-114341132-A | Substituted 1, 3-phenylheteroaryl derivatives and their use in the treatment of diseases | 诺华股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, TMEM161A, TMEM164 | POLB 4320/4885RAB9A 115/4885NPC1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.